Loading organizations...
§ Private Profile · Toulouse, Midi-Pyrenees, France
Biotech company developing low-fucose monoclonal antibodies for gynecological cancers, focused on immuno-oncology.
GamaMabs Pharma is a clinical-stage biotechnology company based in Paris and Toulouse, France, that develops optimized therapeutic monoclonal antibodies for targeted cancer treatment. The organization utilizes its proprietary EMABling platform, originally acquired from LFB, to create low-fucose antibodies designed to enhance immune cell activation against ovarian and other gynecological malignancies. Operating with a lean operational structure of approximately seven employees, the business generated $7 million in reported revenue and raised $22.3 million in total venture funding. Its financial backing includes a €15 million Series B financing round led by Edmond de Rothschild Investment Partners, alongside additional investments from InnoBio and Alto Invest. After advancing its lead candidate into clinical trials, the company successfully sold its primary immuno-oncology asset to Exelixis in 2021. GamaMabs Pharma was founded in 2013 by chief executive officer Stéphane Degove.
GamaMabs Pharma has raised $20.6M across 2 funding rounds.
GamaMabs Pharma has raised $20.6M in total across 2 funding rounds.
GamaMabs Pharma has raised $20.6M across 2 funding rounds. Most recently, it raised $16.4M Series B in December 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2015 | $16.4M Series B | — | Alto Invest, Innobio, IRDInov, IXO Private Equity | Announced |
| Sep 30, 2013 | $4.2M Venture Round | Philippe Boucheron | IRDInov, IXO Private Equity, Denis Soubeyran | Announced |
GamaMabs Pharma has raised $20.6M in total across 2 funding rounds.
GamaMabs Pharma's investors include Alto Invest, InnoBio, IRDInov, iXO Private Equity, Philippe Boucheron, Denis Soubeyran.